as on February 3, 2026 at 2:29 am IST
Day's Low
Day's High
3.45%
Downside
3.45%
Upside
52 Week's Low
52 Week's High
7.74%
Downside
786.21%
Upside
Check Vistagen Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$24.7M
EPS (TTM)
-1.8275
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
0PEG Ratio
0EBITDA
-65.3M
Revenue (TTM)
721.0K
Profit Margin
0.00%
Return On Equity TTM
-78.13%
Compare market cap, revenue, PE, and other key metrics of Vistagen Therapeutics Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $24.7M | -99.11% | NA | 0.00% | |
| BUY | $122.3B | 123.7% | 33.56 | 31.35% | |
| BUY | $47.7B | 124.2% | 1246.03 | 1.36% | |
| NA | $37.4B | NA | 662.33 | 1.38% | |
| BUY | $80.8B | 53.72% | 18.28 | 32.13% |
The Vistagen Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Vistagen Therapeutics Inc investment value today
Current value as on today
₹25,124
Returns
Returns from Vistagen Therapeutics Inc Stock
Dollar Returns*
₹5,193 (+5.19%)
Based on 10 analysts
90.00%
Buy
10.00%
Hold
0.00%
Sell
Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Vistagen Therapeutics Inc. Average target price of $0.97
Get share price movements and forecasts by analysts on Vistagen Therapeutics Inc.
What analysts predicted
40.21%UPSIDE
Target Price
$0.97
Current Price
$0.58
Analyzed by
10 Analysts
Target
$0.97
Vistagen Therapeutics Inc target price $0.97, a slight upside of 40.21% compared to current price of $0.58. According to 10 analysts rating.
Search interest for Vistagen Therapeutics Inc Stock has decreased by -46% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 31 January
Sun, 05:05 AM
-Rosen Law Firm reminds Vistagen investors of March 16, 2026, lead plaintiff deadline in securities class action regarding misleading statements.
Sat, 06:42 PM
-Faruqi & Faruqi investigates claims against Vistagen following failed PALISADE-3 trial results, reminding investors of the March 16, 2026 deadline.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Revenue Rich
![]()
Revenue is up for the last 3 quarters, -15.0K → 258.0K (in $), with an average increase of 55.8% per quarter
Against Peers
![]()
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 34.3% return, outperforming this stock by 127.9%
Against Peers
![]()
In the last 1 year, Beone Medicines Ltd has given 54.5% return, outperforming this stock by 134.6%
Price Dip
![]()
In the last 3 months, VTGN stock has moved down by -86.3%
Profit Down
![]()
Netprofit is down for the last 3 quarters, -13.63M → -19.41M (in $), with an average decrease of 19.7% per quarter
| Organisation | Vistagen Therapeutics Inc |
| Headquarters | 343 Allerton Avenue, South San Francisco, CA, United States, 94080 |
| Industry | Health Technology |
| CEO | Mr. Shawn K. Singh J.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Mr. Joshua S. Prince M.B.A. | Chief Operating Officer |
Mr. Reid G. Adler Esq., J.D. | Chief Legal Officer |
Ms. Michelle Peters Wellington | Vice President of Communications |
Dr. Allen Easley Cato III, M.D., Ph.D. | Senior Vice President of Integrated Drug Development |
Dr. Mark J. Ginski Ph.D. | Senior VP and Head of Chemistry, Manufacturing & Controls |
Mr. Shawn K. Singh J.D. | President, CEO & Director |
Mr. Nick B. Tressler M.B.A. | CFO, Principal Financial & Accounting Officer and Treasurer |
Mr. Mark Adrian McPartland | Senior Vice President of Investor Relations |
Ms. Elissa Cote | Chief Corporate Development Officer |
Ms. Trisha Fitzmaurice | Senior Vice President of Human Resources |
Vistagen Therapeutics Inc share price today is $0.58 as on at the close of the market. Vistagen Therapeutics Inc share today touched a day high of $0.6 and a low of $0.56.
Vistagen Therapeutics Inc share touched a 52 week high of $5.14 on and a 52 week low of $0.54 on . Vistagen Therapeutics Inc stock price today i.e. is closed at $0.58,which is 88.72% down from its 52 week high and 8.39% up from its 52 week low.
Vistagen Therapeutics Inc market capitalisation is $0.00T as on .
Indian investors can start investing in Vistagen Therapeutics Inc (VTGN) shares with as little as ₹91.486 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹914.86 in Vistagen Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Vistagen Therapeutics Inc share’s latest price of $0.58 as on February 3, 2026 at 2:29 am IST, you will get 17.2414 shares of Vistagen Therapeutics Inc. Learn more about
fractional shares .
Vistagen Therapeutics Inc stock has given -99.11% share price returns and 25.75% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?